GPC Biotech AG (Frankfurt Stock Exchange: GPC) today reported that
pre-clinical data on RGB-286638, the Company’s multi-targeted protein
kinase inhibitor, are being presented at the American Association for
Cancer Research (AACR) 100th Annual Meeting in Denver,
Colorado. Researchers from the Dana-Farber Cancer Institute and the
Massachusetts General Hospital Cancer Center (MGH), Boston,
Massachusetts gave an oral presentation entitled, “A Novel
Multi-Targeted Small Molecule Inhibitor RGB-286638 Triggers Apoptosis
and Necrosis in Multiple Myeloma via Dual Cell Death Pathways.” The data
show that RGB-286638 demonstrates in vivo activity in several
pre-clinical models of multiple myeloma. The compound also induces cell
death in multiple myeloma cells independent from the p53 status; p53 is
a gene involved in the control of cell proliferation.
“The data presented today by the MGH/Dana-Farber further support the
potential role of RGB-286638 in the treatment of multiple myeloma,” said
Bernd Seizinger, M.D., Ph.D., Chief Executive Officer of GPC Biotech.
“Based on these data, we are working with the MGH/Dana-Farber team to
design a Phase 1 clinical study in patients with hematological tumors,
including multiple myeloma.”
Additionally, pre-clinical data on RGB-286638 in solid tumor cell lines
are being presented by GPC Biotech researchers in a poster entitled,
“RGB-286638, a multi-targeted protein kinase inhibitor, induces
apoptosis involving the inhibition of RNA polymerase II
carboxyl-terminal domain phosphorylation and the loss of the
anti-apoptotic BCL2 family member Mcl-1” (Abstract #3265). These data
demonstrate that RGB-286638 induces rapid tumor cell killing at very low
doses. Additionally, RGB-286638 shows a potent profile of activities
across a broad range of solid tumor cell lines, including cell lines
originated from prostate, pancreas and kidney cancers. A Phase 1 trial
evaluating RGB-286638 in patients with advanced solid tumors is
currently underway in Europe.
About RGB-286638
RGB-286638 is a multi-targeted protein kinase inhibitor currently in
Phase 1 clinical testing. The RGB-286638 compound has been shown to
inhibit the processes controlling cell division in cancer cells by
targeting multiple cyclin-dependent kinase proteins involved in
regulating the cell cycle. RGB-286638 has also been shown to induce
apoptosis (programmed cell death) and to inhibit other important protein
kinases involved in the proliferation of cancer cells.
